Drugs / DNB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00683501 | Oct 2007 → Aug 2008 | glaucoma, ocular hypertension | Danube Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00683501 ↗ |
| Route | Oral | “administered twice daily (bid) per os (p.o.) as an anti-ocular hypertensive agent” NCT00683501 ↗ |